Harmony BiosciencesHRMY
HRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Employees: 246
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
119% more call options, than puts
Call options by funds: $4.39M | Put options by funds: $2M
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
29% more capital invested
Capital invested by funds: $1.54B [Q2] → $1.99B (+$449M) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
6% more funds holding
Funds holding: 218 [Q2] → 230 (+12) [Q3]
2.34% less ownership
Funds ownership: 89.81% [Q2] → 87.48% (-2.34%) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 86
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
17%
upside
Avg. target
$56
64%
upside
High target
$75
120%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 120%upside $75 | Buy Initiated | 17 Dec 2024 |
Cantor Fitzgerald Charles Duncan 39% 1-year accuracy 32 / 82 met price target | 70%upside $58 | Overweight Maintained | 30 Oct 2024 |
Oppenheimer Francois Brisebois 43% 1-year accuracy 15 / 35 met price target | 73%upside $59 | Outperform Reiterated | 30 Oct 2024 |
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target | 53%upside $52 | Buy Reiterated | 30 Oct 2024 |
Raymond James Danielle Brill 50% 1-year accuracy 7 / 14 met price target | 17%upside $40 | Outperform Reinstated | 10 Oct 2024 |
Financial journalist opinion
Based on 18 articles about HRMY published over the past 30 days
Neutral
Accesswire
6 days ago
Levi & Korsinsky Announces an Investigation on Behalf of Harmony Biosciences Holdings, Inc. (HRMY) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
1 week ago
Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
PRNewsWire
1 week ago
HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , Dec. 18, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P.
Neutral
Accesswire
1 week ago
Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
1 week ago
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
1 week ago
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
1 week ago
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
2 weeks ago
Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY)
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neutral
Accesswire
2 weeks ago
Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - HRMY
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Charts implemented using Lightweight Charts™